Litcius/Paper detail

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial

Yvonne M. Mowery, Karla V. Ballman, Angela Hong, Scott M. Schuetze, Andrew J. Wagner, Varun Monga, Rachel S. Heise, Steven Attia, Edwin Choy, Melissa Burgess, Susie Bae, David Pryor, Brian Andrew Van Tine, Gabriel Tinoco, Bartosz Chmielowski, Carolyn Freeman, Alessandro Gronchi, Christian F. Meyer, Mark A. Dickson, Lee Hartner, Lara E. Davis, Benjamin Powers, Everett J. Moding, Kent J. Weinhold, Matt van de Rijn, Brian E. Brigman, Richard F. Riedel, David G. Kirsch

2024The Lancet78 citationsDOIOpen Access PDF

Topics & Concepts

MedicineSurgerySoft tissue sarcomaRadiation therapyStage (stratigraphy)PembrolizumabSoft tissueClinical trialRandomized controlled trialSarcomaIntraoperative radiation therapyCancerInternal medicineImmunotherapyPathologyPaleontologyBiologySarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsSurgical site infection prevention
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial | Litcius